STXS logo

STXSStereotaxis Inc

$1.85
$0.03
(1.65%)
Today
Updated: 01:02 PM EDT
EarningsAug 14
Mkt Cap$177.88M
Vol58,816.00
News
all
press releases
ISRG's Capital Placement Surge: Demand Strength or Upgrade Cycle Peak?
ISRG placed 431 da Vinci systems in Q1 2026, but rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven.
Zacks
News Placeholder
More News
News Placeholder
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
Zacks
News Placeholder
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +25.00% and -30.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of -25.00% and +3.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +14.30% and +6.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +32.78% and +2.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
Zacks
News Placeholder
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.
Zacks
News Placeholder
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
STXS jumps on FDA clearance of Synchrony system, a 4K platform integrating cath lab tech with cloud connectivity to boost workflow, precision and digital surgery.
Zacks
News Placeholder
Intuitive Surgical Under Pressure in China: Can It Defend Its Position?
ISRG faces rising pricing pressure in China as local rivals gain ground, but its ecosystem, local manufacturing and disciplined pricing aim to defend its position.
Zacks
<
1
2
...
>

Advertisement|Remove ads.